Taiwan Business TOPICS Local pharmaceutical firm Golden Biotechnology Corp. independently developed Antroquinonol
(Hocena®), a novel small-molecule drug, and is now testing its use for treatment of COVID-19. Photo: Golden Biotechnology Corp.
Despite rigorous border control and strict measures, COVID-19 has made its way into Taiwan. Now businesses, researchers, and government are working on innovations that will put Taiwan back in business.
Until recently, Taiwan had a remarkable success record in containing the spread of COVID-19 and maintaining normality for its citizens. While hospitals worldwide had their capacities stretched to their limits, Taiwan reported approximately 1,200 local cases and 11 related deaths in 14 months. However, in May, a few local clusters resulted in a significant spread of the coronavirus around the island.
A drug candidate developed by Golden Biotechnology Corp is to enter phase 2 clinical trials patients in the US for treatment of severely ill COVID-19, pending authorization by the authorities, the Taiwanese drugmaker said.
The drug, called antroquinonol, is undergoing phase 2 clinical trials in the US, Peru and Argentina, where 174 hospital patients with mild to moderate COVID-19 symptoms are enrolled in the double-blind placebo study, the company said in statement on Wednesday last week.
Preliminary results of the phase 2 trials in the US were commended by an independent data monitoring committee assigned to the trials by the US
Taipei, June 4 (CNA) A drug candidate developed by a Taiwanese company for the treatment of COVID-19 will be administered to seriously ill patients in its Phase II clinical trials in the United States, pending authorization by the relevant authorities, according to the developer Golden Biotechnology Corp.
Share this article
Share this article
TAIPEI, Feb. 4, 2021 /PRNewswire/ Golden Biotechnology Corp.(TPEx:4132)( GoldenBiotech ), a leading Taiwanese biopharmaceutical company, announced that it has made two achievements for its Covid-19 new drug candidate Antroquinonol
® (HOCENA
®): receiving positive response after DMC review in Phase 2 clinical trial and signed first agreement in global licensing progress. GoldenBiotech receives in Jan. the Positive Response from DMC, an US FDA approved independent Data Monitoring Committee for its Phase 2 Covid-19 trial in the USA. The clinical trial data of the first set of patients in the Phase 2 trial were unblinded and reviewed by the DMC on the request of FDA. The review approved by the DMC as the positive response to the clinical trial with no need of modification on the trial and can proceed the following recruitment of the patients for the treatment of mild to moderate hospitalized Covid-19 patients. According to the FDA s guida